NOMINATIONS ARE INVITED

for the prestigious

BAILLET LATOUR
HEALTH PRIZE
of
€ 250,000
(Two hundred and fifty thousand euros)

Theme for 2018: Cancer

Recipient 2017 (Neurological Diseases):
Adriano Aguzzi, Switzerland

This personal award is intended to recognize outstanding scientific achievements in biomedical research for the benefit of human health and to encourage the laureate in the pursuit of his/her career. The Prize is open to scientists of all nationalities who have not received an equivalent Prize for their personal use. Exceptionally, the Prize may be shared between two persons who have collaborated over a long period. The laureate will be selected by an international Jury in February 2018.

The themes for the following years will be: Cardiovascular Diseases (2019), Metabolic Disorders (2020), Infectious Diseases (2021), Neurological Diseases (2022).

For more information (including Regulations and Nomination Form) go to www.fondsbaillletlatour.com.

Deadline for nominations: September 30, 2017
THE BAILLET LATOUR HEALTH PRIZE - 2018

HISTORICAL BACKGROUND

1. THE FOUNDATION

The ARTOIS-BAILLET LATOUR Foundation was established on the 1st of March 1974 at the initiative of Count Alfred de BAILLET LATOUR, Director of the ARTOIS Breweries, who presented it with a considerable endowment. The aim of the Foundation was defined as follows:

"The sole aim of the Foundation shall be to encourage and reward achievements of outstanding human value in the Arts and Sciences by means of Prizes, study and travel grants, donations in cash or kind, or by any other means that the Foundation might deem appropriate. The Foundation shall be a non-profit institution and shall have no political, trade-union, philosophical or religious affiliation or allegiance."

The Foundation was initially called “Artois Baillet Latour Foundation”. In 1995 it became the “Interbrew-Baillet Latour Foundation”, in 2005 the “InBev-Baillet Latour Fund” and in 2016 the “Baillet Latour Fund”. The Board of Directors became the Management Board. It is chaired by Mr Jan HUYGHEBAERT, Chairman of the Board of Directors of KBC Group.

2. THE PRIZE

To implement the wishes of Count Alfred de BAILLET LATOUR, the Board of Directors of the Foundation decided in 1977 to establish a Prize to be awarded periodically to recognize the merits of a person whose work has contributed prominently to the improvement of human health. The Prize was called ARTOIS-BAILLET LATOUR HEALTH PRIZE until 1995, then INTERBREW-BAILLET LATOUR HEALTH PRIZE until 2005, then INBEV-BAILLET LATOUR HEALTH PRIZE until 2015 and from 2016 on BAILLET LATOUR HEALTH PRIZE. This Prize, which today amounts to two hundred and fifty thousand euros, was awarded every other year until 1999, and every year since 2000.

Since 2006, the Prize is awarded for one of the following domains of medical research: Cancer (2018), Cardiovascular diseases (2019), Metabolic disorders (2020), Infectious diseases (2021), Neurological diseases (2022)

The regulations of the Prize are approved by the Management Board of the Fund. In 2006, the scientific management and selection of the international Selection Panel of the Prize were delegated to a SCIENTIFIC COMMITTEE. This Committee receives administrative support from the Fund for Scientific Research-FNRS (Belgium). Its current composition is as follows: Professors Geert LEROUX-ROELS (President, Universiteit Gent), Jean-Michel FOIDART (Université de Liège), Louis HUE (Université Catholique de Louvain), Margareta IEVEN (Universiteit Antwerpen), Stefan P. JANSSENS (Katholieke Universiteit Leuven), Isabelle SALMON (Université Libre de Bruxelles), Kris THIELEMANS (Vrije Universiteit Brussel).
3. PREVIOUS RECIPIENTS

- **1979**: Sir James W. BLACK (United Kingdom) for contributing to the development of drugs for cardiovascular disorders and gastro-intestinal diseases.

- **1981**: Sir Cyril A. CLARKE (United Kingdom) for basic and clinical contributions to the control of Rhesus haemolytic disease of the newborn.

- **1983**: Jean BERNARD (France) for contributions to the treatment of acute leukaemias and hematosarcomas.

- **1985**: Johannes J. van ROOD (The Netherlands) for contribution to the discovery of the genes and antigens of the major histocompatibility complex of man.

- **1987**: Viktor MÜTT and Tomas HöKFELT (Sweden) for complementary contributions to the elucidation of neuropeptide function.

- **1989**: Walter FERS (Belgium) for contributions to molecular virology and the isolation and expression of lymphokine genes.

- **1991**: Thomas WALDMANN (United States of America) for contributions to the use of monoclonal antibodies in diagnosis and immunotherapy.

- **1993**: Jean-François BOREL (Switzerland) for discovery of the immuno-suppressive agent cyclosporin.

- **1995**: Roger TSIEEN (United States of America) for contribution to the discovery of intracellular signals that are critical for the action of hormones, neurotransmitters, mediators of immunity, and growth factors.

- **1997**: Michael SELA (Israel) for the development of chemically-built peptides that regulate the immune response and of vaccines that could interfere with autoimmune diseases such as multiple sclerosis.

- **1999**: Julien MENDLEWICZ (Belgium) for studies on the genetic basis of manic-depressive psychosis and identification of genetically-based disorders of biological rhythms, sleep and hormone secretion.

- **2000**: Jacques VAN SNICK and Jean-Christophe RENAULD (Belgium) for contributions to the field of cytokines in relation to the regulation of cell proliferation and immune response.

- **2001**: Jan D.A. van EMBDEN (The Netherlands) for work on the rôle of heat shock proteins in inflammation and the genetic characterization of Mycobacterium tuberculosis.

- **2002**: Robert M. KRUG (United States of America) for the discovery of cap-snatching and its importance in viral replication.

- **2003**: Nancy C. ANDREASEN (United States of America) for contributions to the identification, mechanisms and treatment of schizophrenia.

- **2004**: Elio LUGARESI (Italy) for contribution to the field of sleep disorders and discovery of the rôle of Prion gene mutation in Fatal Familial Insomnia.

- **2005**: Désiré COLLEN and Peter CARMEJUT (Belgium) for pioneering work in genetic engineering, development of recombinant tissue plasminogen activator and generation of animal models of human cardiac diseases.
• **2006 : Hidde L. PLOEGH** (United States of America) for work on how cells eliminate misfolded proteins and how viruses evade immune responses.

• **2007 : Peter H. SEEBURG** (Germany) for discovery of fundamental mechanisms of neural transmission in the brain.

• **2008 : Robert A. WEINBERG** (United States of America) for contributions to molecular oncology, including the identification of the retinoblastoma tumor suppressor gene and of mechanisms underlying tumor progression and metastasis.

• **2009 : Kari AITALO** and **Seppo YLÄ-HERTTUALA** (Finland) for contributions in the field of angiogenesis and lymphangiogenesis and their modulation by signaling pathways.

• **2010 : Stephen O’RAHILLY** (United Kingdom) for contributions to our understanding of how alterations in single genes can cause metabolic disorders, especially obesity, in humans.

• **2011 : Jean-Laurent CASANOVA** (United States of America and France) for work on the identification of genes that predispose to human infectious diseases.

• **2012 : Gero MIESENBÖCK** (United Kingdom) for having pioneered optogenetic approaches to manipulate neuronal activity and to control animal behaviour.

• **2013 : Carlo Maria CROCE** (United States of America) for his discovery that non-coding RNAs are involved in cancer pathogenesis.

• **2014 : Harry C. DIETZ** (United States of America) for his contributions to the genetics, pathobiology and medical treatment of Marfan syndrome and other vascular disorders.

• **2015 : Bruce M. SPIEGELMAN** (United States of America) for his contributions to the understanding of adipose tissue function, differentiation and pathophysiology.

• **2016 : Charles M. RICE** (United States of America) for his outstanding contributions to unravel the complex interactions between Hepatitis C virus and humans.

• **2017 : Adriano AGUZZI** (Switzerland) for his groundbreaking molecular studies of the pathogenic mechanisms of prion-mediated neurological diseases.

20.3.2017
BAILLET LATOUR HEALTH PRIZE 2018

"CANCER"

REGULATIONS

1. THE "BAILLET LATOUR HEALTH PRIZE"

This personal award is granted every year for outstanding achievements in biomedical research for the benefit of human health. It was established to recognize scientific merit and to encourage the laureate in the pursuit of his/her creative research, and is therefore intended for currently active biomedical scientists and not a "crown at the end of a scientific career". Exceptionally, the Prize may be shared by two people who have collaborated closely over a long period. The current value of the Prize is € 250,000 (two hundred and fifty thousand euros).

2. THEMES

The theme for 2018 is "Cancer". The themes for the next four years will be "Cardiovascular Diseases", "Metabolic Disorders", "Infectious Diseases", "Neurological Diseases".

3. NOMINATIONS

The Prize is open to scientists of any nationality who have not previously received an equivalent or higher prize for their personal use. Candidates may not apply themselves, but must be nominated by a person who is duly qualified to assess their work, using the form provided at www.fondsbailletlatour.com. The nomination file for the 2018 Prize must be sent electronically to prix@frs-fnrs.be no later than September 30, 2017 (this is a strict deadline). Incomplete files will be rejected outright.

4. SELECTION PANEL

This Panel, appointed by the Baillet Latour Scientific Committee for Medical Research, consists of seven non-Belgian scientists who are experts in the field of research chosen as theme of the Prize. The Scientific Committee selects one member of the Panel to act as Chairperson. Panel members may not nominate candidates. The composition of the Panel and the name of the laureate remain confidential until the award ceremony.

5. ADMINISTRATIVE INFORMATION

The Scientific Committee is entitled to settle any questions related to the admissibility of nominations. The awarding of the Prize is final, without appeal. Nominations and reports relating to the awarding of the Prize may not be revealed.

20. 03. 2017